Microviable Therapeutics Announces 1.5 Million Euros Investment to Advance the Company´s Microbiota-Derived Biotherapeutic Products
19.4.2022 12:00:00 EEST | Business Wire | Press release
Microviable Therapeutics SL, a preclinical stage biotechnology company developing orally administered biological drugs based on microbiota-derived products, announced 1.5 million euros seed funding from the private medical group Inmunomet Intolerancia y Disbiosis SL.
Microviable will use the seed funding to enhance their therapeutic development platform and advance their pipeline to the clinical stage. The lead product, MVT-201, is under evaluation at pre-clinical stage with positive results, and it is an unique in its kind biological drug based on complete microbiota (HiPMTM) for undisclosed targets. The microbiota-derived product development platform also includes rationally design and defined bacterial consortia that will be advanced with this funding.
This investment will enable to consolidate Microviable’s growth and focus towards the therapeutics, while increasing their facilities and headcount.
“We are really excited for Microviable´s future and grateful for this opportunity to bring novel solutions to healthcare with the ultimate goal of improving the patients’ quality of life”, said Claudio Hidalgo Cantabrana, PhD, co-founder and CEO at Microviable. “We wanted a strategic partner that shares our vision of using microbiota-derived biological drugs to treat patients while providing smart capital, and Inmunomet fulfills all of our expectations”.
Inmunomet is a private medical group specialized in intolerances and gut dysbiosis related disorders with strong experience on the clinic. With this investment, Inmunomet is seeking to be part of Microviable´s growth being ahead on the development of novel solutions based on microbiota-derived biotherapeutic products. Inmunomet provides not only the funding but smart capital and synergies on the clinic, very well aligned with Microviable focus and providing access to the real-world clinical needs to address unmet challenges in human health.
About Microviable
Microviable Therapeutics SL, spun out from the Spanish National Research Council in 2016, focused on developing novel technologies and therapeutic products from the microbiota. Over the last years, Microviable lunched a disruptive product for microbiota sampling that has grown exponentially into an international market with clients across fifteen different countries. Moreover, it has developed a unique technology to store human microbiota for downstream therapeutic applications. Currently, Microviable’s platform together with its large and diverse proprietary bacterial culture collection, has enabled the development of two different products, a unique in its kind product of complete microbiota and rationally defined bacterial consortia.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220419005270/en/
Contact information
Claudio Hidalgo Cantabrana, PhD
claudio.hidalgo@microviable.com
(+34)670034435
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways to Attend Needham Virtual Healthcare Conference on April 14, 20268.4.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Needham Virtual Healthcare Conference on April 14, 2026 and will participate in a fireside chat at 12:45 pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational
Cyviz Launches Unified Software Platform to Support Complex Environments8.4.2026 12:00:00 EEST | Press release
Cyviz AS announces the launch of its enhanced software platform, marking a milestone in the company’s strategic transition toward becoming a technology‑ and platform‑led company. The Cyviz Software Platform helps organizations monitor, manage, and optimize complex AV and IoT environments through a single, unified software layer. Across industries such as energy, defense, transportation, consulting, and large enterprise environments, organizations increasingly rely on complex, multivendor technology ecosystems to support critical operations. These are often managed using fragmented tools, resulting in limited visibility, higher operational risk, and reactive maintenance. Cyviz’ platform addresses this challenge by unifying monitoring and management across technologies, vendors, and locations. With real-time insights, proactive alerts, and centralized control, organizations can move from reactive incident handling to more predictable and resilient operations. “Many organizations are stru
Reply Selected by Microsoft as Launch Partner for Agent 365, Supporting the Governance and Scaling of AI agents8.4.2026 11:17:00 EEST | Press release
Reply [EXM, STAR: REY] has been confirmed one of a small number of Launch Partners for Agent 365, supporting the general availability of Microsoft's new platform designed to provide enterprise-grade governance, observability and lifecycle management for AI agents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260408212380/en/ Through this collaboration with Microsoft, Reply reinforces its commitment to enabling organisations to implement artificial intelligence responsibly and at scale, supporting long-term digital transformation objectives. Microsoft Agent 365 introduces a structured framework enabling organisations to deploy, monitor and manage AI agents consistently across business functions. As artificial intelligence becomes embedded in core operational processes, Agent 365 provides clarity, control and accountability, ensuring that AI-driven activities remain transparent, secure and aligned with organisational objecti
HPE Takes Licence to Patents Offered Through the Sisvel Wi-Fi Multimode Pool8.4.2026 11:00:00 EEST | Press release
Hewlett Packard Enterprise (HPE) has become the latest company to take a licence to the patents offered through the recently launched Sisvel Wi-Fi Multimode pool. It joins Sony Group Corporation, Huawei, Panasonic, Philips and ZTE as a licensee of the programme. The latter four are also licensors, along with KPN, Mitsubishi Electric, Orange, Aegis 11 SA (a Sisvel affiliate), SK Telecom and Wilus. HPE is a major presence in the global WLAN market and is a leading manufacturer of both consumer and enterprise routers. The deal with Sisvel was reached on an amicable basis. The Sisvel Wi-Fi Multimode pool is the successor programme to the Sisvel Wi-Fi 6 patent pool. Over a three-year period, this closed agreements with nearly 40 companies, including Acer, Netgear, Cisco and HP. Covering Wi-Fi 7 as well as 6, the Multimode programme offers an efficient way to access essential Wi-Fi rights for years to come. “We are delighted to welcome Hewlett Packard Enterprise as the latest licensee of the
Zyxel and Openreach Team Up to Reduce Plastic Waste in Full Fibre Installations8.4.2026 11:00:00 EEST | Press release
A new partnership between Zyxel Communications and Openreach is helping to cut plastic and packaging waste from the UK’s Full Fibre rollout - by deploying re-cycled ‘modems’ to connect customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260408766604/en/ Openreach - GPON ONT Zyxel is deploying a range of new Optical Network Terminals (ONTs) - the wall-mounted box of electronics that converts optical signals into electrical ones used by household devices - with re-engineered casings made from 95 per cent recycled plastic.1 Openreach engineers have already installed half a million of Zyxel’s sustainable ONTs and the network provider expects to install even more this year as customers upgrade to Full Fibre - the UK’s most reliable broadband technology. The GPON2 devices use recycled plastic in their construction and arrive in zero‑plastic minimal packaging made from recycled materials. Openreach is working with Zyxel and o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom